

## i4i – Invention for Innovation Programme

**Dr Ruth Nebauer** 

Innovation Programmes
Central Commissioning Facility




#### Who we are & what we do

- NIHR translational funding scheme
- Support collaborative R&D and clinical adoption
- Innovative healthcare technologies
  - Medical devices
  - Active implantable devices
  - In vitro diagnostics
- De-risk projects for follow-on investment
- Led by Programme Director, Martin Hunt
- Supported by a team of Programme Managers


## NHS National Institute for Health Research

#### i4i in the NIHR






## i4i in the funding landscape




## i4i bridges the medtech 'valley of death'






# i4i funds any area of clinical need





## i4i funds projects with lead organisations across England











- i4i Product Development Awards
   (<a href="http://www.nihr.ac.uk/funding/i4i-product-development-awards.htm">http://www.nihr.ac.uk/funding/i4i-product-development-awards.htm</a>)
- i4i Challenge Awards
   (<a href="http://www.nihr.ac.uk/funding/i4i-challenge-awards.htm">http://www.nihr.ac.uk/funding/i4i-challenge-awards.htm</a>)

36 months

78
active
projects

£3.25M largest award

£77M total spend



## Why apply to i4i?

- Dedicated medtech funding programme
- Uncapped funding amount
- Available source of early funding for SMEs
- Milestone-based awards to de-risk
- Commercially oriented panel supported by peer review
- Guidance and advice through RSG/IPMG
- Favourable independent review by RAND¹

<sup>1 &#</sup>x27;The NIHR Invention for Innovation (i4i) programme. A review of progress and contributions to innovation in healthcare technologies'

#### **RAND** review of i4i



'...bridging the valley of death'

- i4i rare funder of high risk early innovation
- Funding process helps proposal improvement
- Willing to support not only usual suspects
- Open to diverse themes and disease areas
- Adaptable and responsive funding source
- Less bureaucracy than other funders
- Valuable support from i4i team
- Prestige of i4i award opens up doors

'The i4i team was instrumental in raising the visibility and the overall impact of the work.'

'When we seek advice from NHS stakeholders....they are more willing to help if you have an NIHR award.'

## **Funding process**





Peer and lay review



Stage 1

Stage 2

Preliminary scrutiny

Panel assessment





## A successful application

Proof-of-concept

Clinical need

**Innovation** 

Project plan

**Project team** 

IP & commercial strategy

Patient and public involvement


NHS adoption

Value for money

### Fast DNA testing platform Quantu/MD<sub>4</sub>



- QuantuMDx Group Ltd, £1.1M for 3 years
- Pre-alpha prototype developed
- Leveraged EU (€5.2M) and Angel (\$8.42M) funding
- Expected product launch in Q3 2016
- Robust nanowire sensor and new sequencing chemistry
- Result in 15min, significant cost reduction
- Global market for platform £100bn







- Oxford University, £0.5M for 3 years
- Clinical trial to test retinal implants in patients who have become blind
- Implants will be given to six patients
- Two year follow up period to review the performance of the implant
- One of the patients (Rhian Lewis)
   appeared on BBC's Trust Me I'm a
   Doctor programme in January 2016





## **Upcoming calls**

- 12<sup>th</sup> Product Development Awards call
  - Opens 6 April 2016
  - Stage 1 deadline 1 June 2016
  - Shortlisting mid-July
  - Stage 2 deadline 14 September 2016
  - Panel meetings in mid-November
- 13<sup>th</sup> Product Development Awards call &
   7<sup>th</sup> Challenge Awards call opening in autumn

## Thank you



#### i4i – Invention for Innovation

NIHR Central Commissioning Facility Grange House, 15 Church Street Twickenham TW1 3NL

#### Contact us for advice and specific guidance:



T 020 8843 8015

E <u>i4i@nihr.ac.uk</u>

W <a href="http://www.nihr.ac.uk/funding/invention-for-innovation.htm">http://www.nihr.ac.uk/funding/invention-for-innovation.htm</a>

**Disclaimer:** Please note that all case studies present independent research funded by the NIHR. The views are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.